tiprankstipranks
Evolus, Inc. Reports Strong Q3 2024 Growth
Company Announcements

Evolus, Inc. Reports Strong Q3 2024 Growth

Evolus, Inc. ( (EOLS) ) has released its Q3 earnings. Here is a breakdown of the information Evolus, Inc. presented to its investors.

Don't Miss our Black Friday Offers:

Evolus, Inc. is a global performance beauty company focused on aesthetics, renowned for its flagship product Jeuveau, a neurotoxin dedicated solely to aesthetic purposes. With its innovative digital platforms and customer-centric model, Evolus is expanding its portfolio with injectable hyaluronic acid gels.

Evolus recently reported its financial results for the third quarter of 2024, highlighting a 22% increase in total net revenue, reaching $61.1 million compared to Q3 2023. The company is experiencing significant growth, driven by consumer engagement and innovative product launches, with a notable expansion into the European market.

Key financial highlights include the addition of over 600 new customer accounts, bringing the total to nearly 14,500, and a 70% reorder rate. Evolus Rewards™ loyalty program surpassed one million members, and the company launched Club Evolus™, a subscription-based program. Despite a recorded loss from operations, the company’s strategic growth initiatives and new product launches are set to bolster its market presence.

Evolus has narrowed its full-year 2024 net revenue guidance to between $260 million and $266 million, indicating a year-over-year growth of 29% to 32%. The company is preparing for the U.S. launch of its Evolysse™ injectable HA gels, with FDA approval expected by September 2025, and anticipates reaching $700 million in revenue by 2028.

Looking ahead, Evolus is poised to leverage its existing infrastructure and expand its market presence, with a target operating margin of at least 20% by 2028. The company remains committed to enhancing its aesthetic portfolio and maintaining its upward growth trajectory in the beauty industry.

Related Articles
TheFlyEvolus reports Q3 EPS (30c), consensus (10c)
TheFlyEvolus sees FY24 revenue $260M-$266M, consensus $266.1M
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App